| Kevin Kelly Appointed to ODAC
Congratulations to Dr. Kevin Kelly who was appointed to the FDA's Oncologic Drugs Advisory Committee (ODAC). One of 13 committee members, Kevin will play an integral role in reviewing new drugs to treat cancer. The committee assesses and evaluates data concerning the safety and effectiveness of marketed and investigational human drug products for use in the treatment of cancer and makes appropriate recommendations to the Commissioner of Food and Drugs, Dr. Margaret Hamburg.
Ocular Oncology Program
I am delighted that Dr. Miguel Materin recently joined Yale Cancer Center as Director of Ocular Oncology. Dr. Materin brings a new level of experience to Yale to treat patients with eye cancers and will build on the already strong Department of Ophthalmology and the Yale Cancer Center Melanoma Program. We are currently working together to develop plans to establish an ocular oncology unit in Smilow Cancer Hospital.
|
Smilow Update
Committee Progress
There is significant activity taking place among the Smilow transition teams as they prepare for the initial phase of occupancy, scheduled to begin in just over seventeen weeks. Construction remains on schedule for an October 26th opening of Radiation Oncology in the Lower Level.
The Occupancy Planning team continues to work with contractors and internal departments to coordinate construction, equipment installation, move planning, and all other building-related tasks. The Education and Orientation team is currently training orientation tour guides and developing training materials and will shortly begin producing the orientation video, which will include interviews with Smilow leadership and patients. The Operations Planning team is dividing into task forces of 50 plus people to create the individual operating plans for their department. These plans will be aligned across services to ensure consistency and standardization throughout Smilow Cancer Hospital.
For more information on the transition, David Vinas, Transition Leader, can be reached at 688-2973.
|
Shared Resource Highlight
Genetic Counseling Program
The Yale Cancer Genetic Counseling Program provides clinical services to individuals at increased risk for hereditary cancer due to their personal or family histories of cancer. This program is based on a three part counseling model consisting of 1) obtaining a detailed medical and three-generational family history; 2) calculating a personalized risk assessment and providing options for prevention, surveillance, and genetic testing; 3) coordinating and interpreting genetic testing, and developing a personalized management plan based on the test results.
Ellen Matloff, MS, Director (203) 764-8400 Learn More >>
|
Recent Publications
Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer.
Cocco E, Bellone S, El-Sahwi K, Cargnelutti M, Casagrande F, Buza N, Tavassoli FA, Siegel ER, Visintin I, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.
Br J Cancer. 2009 Jun 16.
Read More >>
Recurrent cutaneous toxic erythema induced by gemcitabine in a patient with pancreatic cancer.
Li J, Ko CJ, Saif MW.
Cutan Ocul Toxicol. 2009 Jun 15.
Read More >>
Hypoxia and radiation therapy: past history, ongoing research, and future promise.
Rockwell S, Dobrucki IT, Kim EY, Marrison ST, Vu VT.
Curr Mol Med. 2009 Jun;9(4):442-58.
Read More >>
Intake of meat, meat mutagens, and iron and the risk of breast cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
Ferrucci LM, Cross AJ, Graubard BI, Brinton LA, McCarty CA, Ziegler RG, Ma X, Mayne ST, Sinha R.
Br J Cancer. 2009 Jun 9.
Read More >>
Changes in gene expression predicting local control in cervical cancer: results from Radiation Therapy Oncology Group 0128.
Weidhaas JB, Li SX, Winter K, Ryu J, Jhingran A, Miller B, Dicker AP, Gaffney D.
Clin Cancer Res. 2009 Jun 15;15(12):4199-206.
Epub 2009 Jun 9.
Read More >>
Primary cutaneous T-cell lymphoma localized to the lower leg: a distinct, locally aggressive cutaneous T-cell lymphoma.
Poligone B, Wilson LD, Subtil A, Heald P. Arch Dermatol. 2009 Jun;145(6):677-82.
Read More >>
High expression of mammalian target of rapamycin is associated with better outcome for patients with early stage lung adenocarcinoma.
Anagnostou VK, Bepler G, Syrigos KN, Tanoue L, Gettinger S, Homer RJ, Boffa D, Detterbeck F, Rimm DL.
Clin Cancer Res. 2009 Jun 15;15(12):4157-64.
Epub 2009 Jun 9.
Read More >>
|
|
|
|
Inside Yale Cancer Center
Thoracic Oncology Program
The Yale Cancer Center Thoracic Oncology Program recently launched a new site devoted to patient care and research activities for lung and esophageal cancer.
Prevalence of Dietary Supplement Use among Cancer Survivors Studied
Drs. Brenda Cartmel and Leah Ferrucci recently published the results of a study analyzing the use of dietary supplements among cancer survivors in Connecticut.
Oncology Congress
Yale Cancer Center is one of the partners for the 5th annual Oncology Congress. Register now to take advantage of special reduced rates. |
Events
June 26; 7:00 AM
Yale ASCO Review 2009
The Anlyan Center
June 30; 8:30 AM
Yale Cancer Center
Grand Rounds
Fitkin Amphitheater
The Road to Therapy of Melanoma in 2009
John Kirkwood, MD
July 20 - 22
Solving Basic and Clinical Research Challenges in Cancer and Beyond
The 2009 caBIG® Annual Meeting
Marriott Wardman Park, Washington, DC
Learn More >>
July 25; 8:00 AM
The Connecticut Challenge
Greenfield Hill, Fairfield
Learn More >>
|
Submissions
Please submit your recent publication and grant announcements to:
Renee Gaudette
Director, Public Affairs and Marketing
renee.gaudette@yale.edu
|
|
|
